Parag V. Meswani
Corporate Officer/Principal en ACADIA PHARMACEUTICALS INC. .
Perfil
Parag V.
Meswani is currently the Senior Vice President-Trofinetide at ACADIA Pharmaceuticals, Inc. Prior to this, he held positions at Biogen, Inc. as the Chief Executive Officer-Commercial Operations, at Spark Therapeutics, Inc. as the Head-US Marketing, and at Sio Gene Therapies, Inc. as the Chief Commercial Officer.
Dr. Meswani has an MBA from The Trustees of Columbia University in The City of New York, an undergraduate and doctorate degree from Ernest Mario School of Pharmacy, and another MBA from Columbia Business School.
Cargos activos de Parag V. Meswani
| Empresas | Cargo | Inicio |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/04/2022 |
Antiguos cargos conocidos de Parag V. Meswani.
| Empresas | Cargo | Fin |
|---|---|---|
| SIO GENE THERAPIES INC. | Director de Operaciones | 06/10/2020 |
| BIOGEN INC. | Corporate Officer/Principal | - |
| SPARK THERAPEUTICS, INC. | Ventas & Marketing | - |
Formación de Parag V. Meswani.
| Ernest Mario School of Pharmacy | Doctorate Degree |
| Columbia Business School | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Spark Therapeutics, Inc.
 Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
- Bolsa de valores
- Insiders
- Parag V. Meswani